111 related articles for article (PubMed ID: 28106301)
1. UXT Is a LOX-PP Interacting Protein That Modulates Estrogen Receptor Alpha Activity in Breast Cancer Cells.
Sánchez-Morgan N; Kirsch KH; Trackman PC; Sonenshein GE
J Cell Biochem; 2017 Aug; 118(8):2347-2356. PubMed ID: 28106301
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of CIN85-mediated invasion by a novel SH3 domain binding motif in the lysyl oxidase propeptide.
Sato S; Zhao Y; Imai M; Simister PC; Feller SM; Trackman PC; Kirsch KH; Sonenshein GE
PLoS One; 2013; 8(10):e77288. PubMed ID: 24167568
[TBL] [Abstract][Full Text] [Related]
3. Alfa-class prefoldin protein UXT is a novel interacting partner of Amyotrophic Lateral Sclerosis 2 (Als2) protein.
Enunlu I; Ozansoy M; Basak AN
Biochem Biophys Res Commun; 2011 Sep; 413(3):471-5. PubMed ID: 21907703
[TBL] [Abstract][Full Text] [Related]
4. The Ras signaling inhibitor LOX-PP interacts with Hsp70 and c-Raf to reduce Erk activation and transformed phenotype of breast cancer cells.
Sato S; Trackman PC; Mäki JM; Myllyharju J; Kirsch KH; Sonenshein GE
Mol Cell Biol; 2011 Jul; 31(13):2683-95. PubMed ID: 21536655
[TBL] [Abstract][Full Text] [Related]
5. The tumor suppressor activity of the lysyl oxidase propeptide reverses the invasive phenotype of Her-2/neu-driven breast cancer.
Min C; Kirsch KH; Zhao Y; Jeay S; Palamakumbura AH; Trackman PC; Sonenshein GE
Cancer Res; 2007 Feb; 67(3):1105-12. PubMed ID: 17283144
[TBL] [Abstract][Full Text] [Related]
6. A loss-of-function polymorphism in the propeptide domain of the LOX gene and breast cancer.
Min C; Yu Z; Kirsch KH; Zhao Y; Vora SR; Trackman PC; Spicer DB; Rosenberg L; Palmer JR; Sonenshein GE
Cancer Res; 2009 Aug; 69(16):6685-93. PubMed ID: 19654310
[TBL] [Abstract][Full Text] [Related]
7. Repression of BCL2 by the tumor suppressor activity of the lysyl oxidase propeptide inhibits transformed phenotype of lung and pancreatic cancer cells.
Wu M; Min C; Wang X; Yu Z; Kirsch KH; Trackman PC; Sonenshein GE
Cancer Res; 2007 Jul; 67(13):6278-85. PubMed ID: 17616686
[TBL] [Abstract][Full Text] [Related]
8. Lysyl oxidase propeptide promotes adipogenesis through inhibition of FGF-2 signaling.
Griner JD; Rogers CJ; Zhu MJ; Du M
Adipocyte; 2017 Jan; 6(1):12-19. PubMed ID: 28452589
[TBL] [Abstract][Full Text] [Related]
9. Expression of the lysyl oxidase propeptide in hepatocellular carcinoma and its clinical relevance.
Zheng Y; Wang X; Wang H; Yan W; Zhang Q; Chang X
Oncol Rep; 2014 Apr; 31(4):1669-76. PubMed ID: 24573150
[TBL] [Abstract][Full Text] [Related]
10. Role of the Unconventional Prefoldin Proteins URI and UXT in Transcription Regulation.
Thomas PA; Mita P; Ha S; Logan SK
Adv Exp Med Biol; 2018; 1106():85-94. PubMed ID: 30484154
[TBL] [Abstract][Full Text] [Related]
11. Determination of cell uptake pathways for tumor inhibitor lysyl oxidase propeptide.
Ozdener GB; Bais MV; Trackman PC
Mol Oncol; 2016 Jan; 10(1):1-23. PubMed ID: 26297052
[TBL] [Abstract][Full Text] [Related]
12. The lysyl oxidase propeptide interacts with the receptor-type protein tyrosine phosphatase kappa and inhibits β-catenin transcriptional activity in lung cancer cells.
Sánchez-Morgan N; Kirsch KH; Trackman PC; Sonenshein GE
Mol Cell Biol; 2011 Aug; 31(16):3286-97. PubMed ID: 21690299
[TBL] [Abstract][Full Text] [Related]
13. Lysyl oxidase propeptide inhibits FGF-2-induced signaling and proliferation of osteoblasts.
Vora SR; Palamakumbura AH; Mitsi M; Guo Y; Pischon N; Nugent MA; Trackman PC
J Biol Chem; 2010 Mar; 285(10):7384-93. PubMed ID: 20048148
[TBL] [Abstract][Full Text] [Related]
14. Ubiquitously expressed transcript is a novel interacting protein of protein inhibitor of activated signal transducer and activator of transcription 2.
Kong X; Ma S; Guo J; Ma Y; Hu Y; Wang J; Zheng Y
Mol Med Rep; 2015 Apr; 11(4):2443-8. PubMed ID: 25434787
[TBL] [Abstract][Full Text] [Related]
15. UXT plays dual opposing roles on SARM-induced apoptosis.
Sethurathinam S; Singh LP; Panneerselvam P; Byrne B; Ding JL
FEBS Lett; 2013 Oct; 587(20):3296-302. PubMed ID: 24021647
[TBL] [Abstract][Full Text] [Related]
16. Targeting lysyl oxidase for molecular imaging in breast cancer.
Wuest M; Kuchar M; Sharma SK; Richter S; Hamann I; Wang M; Vos L; Mackey JR; Wuest F; Löser R
Breast Cancer Res; 2015 Aug; 17(1):107. PubMed ID: 26265048
[TBL] [Abstract][Full Text] [Related]
17. A polymorphism in the lysyl oxidase propeptide domain accelerates carcinogen-induced cancer.
de la Cueva A; Emmerling M; Lim SL; Yang S; Trackman PC; Sonenshein GE; Kirsch KH
Carcinogenesis; 2018 Jul; 39(7):921-930. PubMed ID: 29579155
[TBL] [Abstract][Full Text] [Related]
18. Lysyl oxidase propeptide inhibits prostate cancer cell growth by mechanisms that target FGF-2-cell binding and signaling.
Palamakumbura AH; Vora SR; Nugent MA; Kirsch KH; Sonenshein GE; Trackman PC
Oncogene; 2009 Sep; 28(38):3390-400. PubMed ID: 19597471
[TBL] [Abstract][Full Text] [Related]
19. Regulation of the transcriptional activation of the androgen receptor by the UXT-binding protein VHL.
Chen S; Chen K; Zhang Q; Cheng H; Zhou R
Biochem J; 2013 Nov; 456(1):55-66. PubMed ID: 23961993
[TBL] [Abstract][Full Text] [Related]
20. The apoptotic and anti-proliferative effect of Lysyl oxidase propeptide in Y79 human retinoblastoma cells.
Nagaraj NR; Natarajan SK; Karunakaran C
Mol Vis; 2023; 29():125-139. PubMed ID: 38222455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
